No Data
Neurogene Highlights Progress in Rett Syndrome Program
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)
Neurogene Files to Sell 4M Shares of Common Stock for Holders
Neurogene Inc. Sees Significant Stock Purchases by Samsara BioCapital
12 Health Care Stocks Moving In Tuesday's Pre-Market Session